Skip to main content

Table 3 Post-transplant 2-year outcomes

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

  NRM RI Extensive GVHD GRFS LFS OS
No-ATG 17.3% [13.3–21.7] 27.2% [22.4–32.1] 26.3% [21.2–31.6] 39.6% [34–45.1] 55.4% [49.8–61] 58.9% [53.2–64.6]
ATG 10.7% [7.7–14.2] 22.5% [15.1–30.8] 7.6% [3.5–13.7] 60.1% [51–69.3] 66.8% [58.1–75.6] 71.8% [63.4–80.2]
p value 0.149 0.226 4.7 × 10−5 0.00016 0.044 0.049
  1. ATG anti-thymocyte globulin, GRFS GVHD and relapse-free survival, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, RI relapse incidence